The Potential Prognostic Impact and Intercorrelations between CTLA-4, PD-1/PD-L1 and CD73/A2AR Immune Checkpoint Molecules in Colorectal Cancer

被引：0
|
作者：
Aboelnasr, L. [1 ,2 ]
Abdou, A. [3 ]
机构：
[1] Menoufia Univ Hosp, Menoufia, Egypt
[2] Imperial Coll London, London, England
[3] Menoufia Univ, Menoufia, Egypt
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2023年 / 25卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
ST150
引用
收藏
页码：S140 / S141
页数：2
相关论文
共 50 条
  • [21] PD-L1, PD-1, and CTLA-4 Expression in Invasive Breast Cancer in Young Women
    Obeidin, Farres
    Pincus, Jennifer
    Siziopikou, K. P.
    Blanco, Luis
    MODERN PATHOLOGY, 2019, 32
  • [22] Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
    Cheng, Weishi
    Kang, Kai
    Zhao, Ailin
    Wu, Yijun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [23] Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression
    Skafi, Najwa
    Fayyad-Kazan, Mohammad
    Badran, Bassam
    GENE, 2020, 754
  • [24] Germline variants of the immune checkpoint proteins PD-1, PD-l1 and CTLA-4 and immune tolerance induction outcome in patients with inherited haemophilia A
    Zuccherato, Luciana W.
    Camelo, Ricardo M.
    Chaves, Daniel G.
    Rezende, Suely M.
    HAEMOPHILIA, 2023, 29 (05) : 1366 - 1368
  • [25] Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade
    Sun, Michel M.
    Seleme, Nicolas
    Chen, John J.
    Zekeridou, Anastasia
    Sechi, Elia
    Walsh, Ryan D.
    Beebe, Johanna D.
    Sabbagh, Osama
    Mejico, Luis J.
    Gratton, Sean
    Skidd, Philip M.
    Bellows, David A.
    Falardeau, Julie
    Fraser, Clare L.
    Cappelen-Smith, Cecilia
    Haines, Scott R.
    Hassanzadeh, Bahareh
    Seay, Meagan D.
    Subramanian, Prem S.
    Williams, Zoe
    Gordon, Lynn K.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2021, 41 (04) : 519 - 530
  • [26] Effects and Mechanisms of Checkpoint Inhibitors (CTLA-4, PD-1 and PD-L1 Inhibitors) as New Immunotherapeutic Agents for Bladder Cancer
    Celik, Serdar
    Altun, Zekiye Sultan
    Aktas, Safiye
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2018, 17 (01): : 18 - 25
  • [27] PD-1/PD-L1/CTLA-4 INHIBITOR THERAPY FOLLOWING PROGRESSION ON A DIFFERENT PD-1/PD-L1 INHIBITOR: A CASE SERIES
    Mukkamala, Suresh
    Tawagi, Karine
    Matrana, Marc
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A121 - A121
  • [28] Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
    Ziogas, Dimitrios C.
    Theocharopoulos, Charalampos
    Lialios, Panagiotis-Petros
    Foteinou, Dimitra
    Koumprentziotis, Ioannis-Alexios
    Xynos, Georgios
    Gogas, Helen
    CANCERS, 2023, 15 (10)
  • [29] CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
    Cao, Lu
    Bridle, Kim R.
    Shrestha, Ritu
    Prithviraj, Prashanth
    Crawford, Darrell H. G.
    Jayachandran, Aparna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [30] Investigation of immune checkpoint molecules (CTLA-4, PD-1, PD-L1, Tim-3) expressions in preeclampsia: A comparative study of membranous and soluble forms
    Parhizkar, Forough
    Soltani-Zangbar, Mohammad Sadegh
    Shekari, Najibeh
    Hajiesmailpoor, Zanyar
    Parsania, Sara
    Aghebati-Maleki, Ali
    Aghebati-Maleki, Leili
    HUMAN IMMUNOLOGY, 2025, 86 (03)
12345